Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
DPTX3186 in Wnt-Pathway Activated Solid Tumors
NCT07312903Phase 1Recruiting
- Sponsor
- Dewpoint Therapeutics
- Start
- Jan 2026
- Primary completion
- May 2028
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of DPTX3186 in solid tumor, sponsored by Dewpoint Therapeutics. Primary endpoint: Incidence of treatment emergent adverse events and serious adverse events at 36 months. Started Jan 2026; status: recruiting.
02
Drugs
DPTX3186
03
Conditions
solid tumor
Beyond the preview
Go deeper on NCT07312903.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07312903.